Exp. 1: To determine if Niraparib and anti-PD-L1 therapy can be combined to enhance tumoricidal response . Exp. 2: The major goal of this experiment is to characterize the "BRCAness" phenotype of bladder cancer by quantification of the homologous repair deficiency (HRD) score and genomics scars and the validation of HRD as a biomarker to target PARPi use in patients.
|Effective start/end date||7/11/17 → 7/11/19|
- TESARO, Inc. (Prot #IS00006804)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.